Our Access to Patented Technologies
Stem Cell Culture & Identification
-
CD117/CD34 Identification (Patent No. 2013100XXXXX): A method to isolate high-purity mesenchymal stem cells (MSCs) from the human placenta—essential for developing targeted regenerative treatments.
-
Serum-Free Umbilical Cord MSC Medium (Patent No. ZL2012103XXXXX): Enables large-scale and ethical cultivation of umbilical MSCs without using animal-derived components
Regenerative Wound Healing
-
Skin-Derived MSCs for Healing (Patent No. CN2019104XXXXX): A formulation that accelerates dermal regeneration and wound closure.
-
Skin Regeneration Dressing (Patent No. CN2019107XXXXX): A biomaterial dressing infused with regenerative cell components to enhance tissue recovery.
Cryopreservation & Delivery Platforms
-
Cell Cryopreservation Box (Patent No. 2021112XXXXX: Keeps cells viable for clinical use, revolutionizing stem cell banking.
-
Anti-Tumor Extracellular Vesicle System (Patent No. 2024104XXXXX): Combats immunosuppressive tumor environments and delivers targeted anti-cancer agents.
Exosome & Biologics
-
Stem Cell Exosome Biologics (Patent No. 2022115XXXXX): A long-acting bioagent that utilizes cell-derived exosomes to promote healing, anti-inflammation, and skin rejuvenation.
Immune Cell Therapies
-
T Cell Enrichment via Microcarriers (Patent No. 2023115XXXXX): Enhances immune responsiveness for use in immunotherapy, including cancer and autoimmune applications.
These patents place us at the convergence of regenerative medicine, immunotherapy, and longevity science